Balázs István Tóth
University of Debrecen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Balázs István Tóth.
American Journal of Pathology | 2005
Enikö Bodó; Tamás Bíró; Andrea Telek; Gabriella Czifra; Zoltán Griger; Balázs István Tóth; Alessandra Mescalchin; Taisuke Ito; Albrecht Bettermann; László Kovács; Ralf Paus
The vanilloid receptor-1 (VR1, or transient receptor potential vanilloid-1 receptor, TRPV1) is activated by capsaicin, the key ingredient of hot peppers. TRPV1 was originally described on sensory neurons as a central integrator of various nociceptive stimuli. However, several human skin cell populations are also now recognized to express TRPV1, but with unknown function. Exploiting the human hair follicle (HF) as a prototypic epithelial-mesenchymal interaction system, we have characterized the HF expression of TRPV1 in situ and have examined TRPV1 signaling in organ-cultured human scalp HF and outer root sheath (ORS) keratinocytes in vitro. TRPV1 immunoreactivity was confined to distinct epithelial compartments of the human HF, mainly to the ORS and hair matrix. In organ culture, TRPV1 activation by capsaicin resulted in a dose-dependent and TRPV1-specific inhibition of hair shaft elongation, suppression of proliferation, induction of apoptosis, premature HF regression (catagen), and up-regulation of intrafollicular transforming growth factor-beta(2). Cultured human ORS keratinocytes also expressed functional TRPV1, whose stimulation inhibited proliferation, induced apoptosis, elevated intracellular calcium concentration, up-regulated known endogenous hair growth inhibitors (interleukin-1beta, transforming growth factor-beta(2)), and down-regulated known hair growth promoters (hepatocyte growth factor, insulin-like growth factor-I, stem cell factor). These findings strongly support TRPV1 as a significant novel player in human hair growth control, underscore the physiological importance of TRPV1 in human skin beyond nociception, and identify TRPV1 as a promising, novel target for pharmacological manipulations of epithelial growth disorders.
Trends in Pharmacological Sciences | 2009
Tamás Bíró; Balázs István Tóth; György Haskó; Ralf Paus; Pál Pacher
The newly discovered endocannabinoid system (ECS; comprising the endogenous lipid mediators endocannabinoids present in virtually all tissues, their G-protein-coupled cannabinoid receptors, biosynthetic pathways and metabolizing enzymes) has been implicated in multiple regulatory functions both in health and disease. Recent studies have intriguingly suggested the existence of a functional ECS in the skin and implicated it in various biological processes (e.g. proliferation, growth, differentiation, apoptosis and cytokine, mediator or hormone production of various cell types of the skin and appendages, such as the hair follicle and sebaceous gland). It seems that the main physiological function of the cutaneous ECS is to constitutively control the proper and well-balanced proliferation, differentiation and survival, as well as immune competence and/or tolerance, of skin cells. The disruption of this delicate balance might facilitate the development of multiple pathological conditions and diseases of the skin (e.g. acne, seborrhea, allergic dermatitis, itch and pain, psoriasis, hair growth disorders, systemic sclerosis and cancer).
Experimental Dermatology | 2008
Borbála Kiss; Tamás Bíró; Gabriella Czifra; Balázs István Tóth; Zsófia Kertész; Zita Szikszai; Árpád Z. Kiss; István Juhász; Christos C. Zouboulis; J. Hunyadi
Abstract: Titanium dioxide (TiO2) nanoparticles are ubiquitously used materials in everyday life (e.g. paints, household products and plastic goods). However, despite the wide array of common applications, their pathogenetic role was also suggested under certain conditions (e.g. pulmonary neoplasias and lung fibrosis). From a dermatological point of view, it is also of great importance that TiO2 also serves as a physical photoprotective agent in sunscreens and is widely used in various cosmetic products. However, the effect of TiO2 on human cutaneous functions is still unknown. Therefore, in the current study, we investigated the in vivo penetration of TiO2 via human skin transplanted to immunodeficient mice and, furthermore, we measured the in vitro effects of nanoparticles on various functional properties of numerous epidermal and dermal cells in culture. Hereby, using various nuclear microscopy methods, we provide the first evidence that TiO2 nanoparticles in vivo do not penetrate through the intact epidermal barrier. However, we also report that TiO2, when exposed directly to cell cultures in vitro, exerts significant and cell‐type dependent effects on such cellular functions as viability, proliferation, apoptosis and differentiation. Therefore, our novel findings will hopefully inspire one to systemically explore in future, clinically oriented trials whether there is indeed a risk from micronized TiO2‐containing products on skin with an impaired stratum corneum barrier function.
The FASEB Journal | 2008
Nóra Dobrosi; Balázs István Tóth; Georgina Nagy; Anikó Dózsa; Tamás Géczy; Laszlo Nagy; Christos C. Zouboulis; Ralf Paus; László Kovács; Tamás Bíró
We had previously shown that both locally produced endocannabinoids and exocannabinoids, via cannabinoid receptor‐1 (CB1), are powerful inhibitors of human hair growth. To further investigate the role of the cannabinoid system in pilosebaceous unit biology, we have explored in the current study whether and how endocannabinoids have an impact on human sebaceous gland biology, using human SZ95 sebocytes as cell culture model. Here, we provide the first evidence that SZ95 sebocytes express CB2 but not CB1. Also, prototypic endocannabinoids (arachidonoyl ethanolamide/anandamide, 2‐arachidonoyl glycerol) are present in SZ95 sebocytes and dose‐dependently induce lipid production and (chiefly apoptosis‐driven) cell death. Endocannabinoids also up‐regulate the expression of key genes involved in lipid synthesis (e.g., PPAR transcription factors and some of their target genes). These actions are selectively mediated by CB2‐coupled signaling involving the MAPK pathway, as revealed by specific agonists/antagonists and by RNA interference. Because cells with “silenced” CB2 exhibited significantly suppressed basal lipid production, our results collectively suggest that human sebocytes utilize a paracrine‐autocrine, endogenously active, CB2‐mediated endocannabinoid signaling system for positively regulating lipid production and cell death. CB2 antagonists or agonists therefore deserve to be explored in the management of skin disorders characterized by sebaceous gland dysfunctions (e.g., acne vulgaris, seborrhea, dry skin).—Dobrosi, N., Tóth, B. I., Nagy, G., Dózsa, A., Géczy, T., Nagy, L., Zouboulis, C. C., Paus, R., Kovács, L., Bíró, T. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor‐2‐mediated signaling. FASEB J. 22, 3685–3695 (2008)
Journal of Cancer Research and Clinical Oncology | 2009
Gabriella Czifra; Attila Varga; Katalin Nyeste; Rita Marincsák; Balázs István Tóth; Ilona Kovács; László Kovács; Tamás Bíró
PurposeRecently, functional cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) have been described in human prostate and prostate cancer-derived cell lines where the activation of the receptors resulted in inhibition of cellular growth. We, however, lack the description of the expression of these molecules in human prostate cancer (PCC) and in benign prostate hyperplasia (BPH).MethodsTherefore, immunohistochemistry, Western blotting, and quantitative “real-time Q-PCR were performed to define the expressions of CB1 and TRPV1 in healthy and diseased prostate tissues.ResultsCB1 was identified in epithelial and smooth muscle cells types of the human prostate, whereas TRPV1 was exclusively localized to the mucosal cells. We also found that the expression of CB1 and TRPV1 (both at the protein and mRNA levels) were significantly up-regulated in PCC. However, while the increased expression of TRPV1 showed a proper correlation with increasing PCC tumor grades, such phenomenon was not observed with CB1. In addition, we also measured markedly elevated CB1 levels in BPH tissues whilst the expression of TRPV1 was not altered when compared to healthy control prostate.ConclusionsOur findings strongly argue for that (1) the CB1 and TRPV1 molecules as well as their ligands may indeed possess a promising future role in the treatment of PCC; (2) TRPV1 may also serve as a prognostic factor in PCC; and (3) CB1 may act as a potential target molecule in the therapeutic management of BPH.
Journal of Investigative Dermatology | 2011
István Borbíró; Erika Lisztes; Balázs István Tóth; Gabriella Czifra; Attila Oláh; Attila Gábor Szöllősi; Norbert Szentandrássy; Péter P. Nánási; Zoltán Péter; Ralf Paus; László Kovács; Tamás Bíró
In the current study, we aimed at identifying the functional role of transient receptor potential vanilloid-3 (TRPV3) ion channel in the regulation of human hair growth. Using human organ-cultured hair follicles (HFs) and cultures of human outer root sheath (ORS) keratinocytes, we provide the first evidence that activation of TRPV3 inhibits human hair growth. TRPV3 immunoreactivity was confined to epithelial compartments of the human HF, mainly to the ORS. In organ culture, TRPV3 activation by plant-derived (e.g., eugenol, 10-1,000 μM) or synthetic (e.g., 2-aminoethoxydiphenyl borate, 1-300 μM) agonists resulted in a dose-dependent inhibition of hair shaft elongation, suppression of proliferation, and induction of apoptosis and premature HF regression (catagen). Human ORS keratinocytes also expressed functional TRPV3, whose stimulation induced membrane currents, elevated intracellular calcium concentration, inhibited proliferation, and induced apoptosis. Of great importance, these effects on ORS keratinocytes were all mediated by TRPV3, as small interfering RNA-mediated silencing of TRPV3 effectively abrogated the cellular actions of the above agonists. These findings collectively support the concept that TRPV3 signaling is a significant player in human hair growth control. Therefore, TRPV3 and the related intracellular signaling mechanism might function as a promising target for pharmacological manipulations of clinically relevant hair growth disorders.
Journal of Investigative Dermatology | 2009
Balázs István Tóth; Tamás Géczy; Zoltán Griger; Anikó Dózsa; Holger Seltmann; László Kovács; Laszlo Nagy; Christos C. Zouboulis; Ralf Paus; Tamás Bíró
Transient receptor potential vanilloid-1 (TRPV1), originally described as a central integrator of nociception, is expressed on human epidermal and hair follicle keratinocytes and is involved in regulation of cell growth and death. In human pilosebaceous units, we had shown that TRPV1 stimulation inhibits hair shaft elongation and matrix keratinocyte proliferation, and induces premature hair follicle regression and keratinocyte apoptosis. In the current study, we have explored the role of TRPV1-mediated signaling in sebaceous gland (SG) biology, using a human sebocyte cell culture model (SZ95 sebocytes). Demonstrating that human skin SG in situ and SZ95 sebocytes in vitro express TRPV1, we show that the prototypic TRPV1 agonist, capsaicin, selectively inhibits basal and arachidonic acid-induced lipid synthesis in a dose-, time-, and extracellular calcium-dependent and a TRPV1-specific manner. Low-dose capsaicin stimulates cellular proliferation via TRPV1, whereas higher concentrations inhibit sebocyte growth and induce cell death independent of TRPV1. Moreover, capsaicin suppresses the expression of genes involved in lipid homeostasis and of selected proinflammatory cytokines. Collectively, these findings support the concept that TRPV1 signaling is a significant, previously unreported player in human sebocyte biology and identify TRPV1 as a promising target in the clinical management of inflammatory SG disorders (for example, acne vulgaris).
The FASEB Journal | 2007
Andrea Telek; Tamás Bíró; Enikö Bodó; Balázs István Tóth; István Borbíró; George Kunos; Ralf Paus
Recent studies strongly suggest that the cannabinoid system is a key player in cell growth control. Since the organ‐culture of human hair follicles (HF) offers an excellent, clinically relevant model for complex tissue interaction systems, we have asked whether the cannabinoid system plays a role in hair growth control. Here, we show that human scalp HF, intriguingly, are both targets and sources of endocan‐nabinoids. Namely, the endocannabinoid N‐arachido‐noylethanolamide (anandamide, AEA) as well as the exocannabinnoid Δ (9)‐tetrahydrocannabinol dose‐de‐pendently inhibited hair shaft elongation and the proliferation of hair matrix keratinocytes, and induced intraepithelial apoptosis and premature HF regression (catagen). These effects were inhibited by a selective antagonist of cannabinoid receptor‐1 (CB1). In contrast to CB2, CB1 was expressed in a hair cycle‐dependent manner in the human HF epithelium. Since we successfully identified the presence of endocannabinoids in human HF, our data strongly suggest that human HF exploit a CB1‐mediated endocannabinoid signaling system for negatively regulating their own growth. Clinically, CB1 agonists may therefore help to manage unwanted hair growth, while CB1 antagonists might counteract hair loss. Finally, human HF organ culture offers an instructive, physiologically relevant new research tool for dissecting “nonclassical” effects of endocannabinoids and their receptor‐mediated signaling in general.—Telek, A., Bíró, T., Bodó, E., Tóth, B. I., Borbíró, I., Kunos, G., Paus, R. Inhibition of human hair follicle growth by endo‐ and exocannabi‐noids. FASEB J. 21, 3534–3541 (2007)
The FASEB Journal | 2010
Yuval Ramot; Tamás Bíró; Stephan Tiede; Balázs István Tóth; Ewan A. Langan; Koji Sugawara; Kerstin Foitzik; Arieh Ingber; Vincent Goffin; Lutz Langbein; Ralf Paus
The controls of human keratin expression in situ remain to be fully elucidated. Here, we have investigated the effects of the neurohormone prolactin (PRL) on keratin expression in a physiologically and clinically relevant test system: organ‐cultured normal human hair follicles (HFs). Not only do HFs express a wide range of keratins, but they are also a source and target of PRL. Microarray analysis revealed that PRL differentially regulated a defined subset of keratins and keratin‐associated proteins. Quantitative immunohistomorphometry and quantitative PCR confirmed that PRL up‐regulated expression of keratins K5 and K14 and the epithelial stem cell‐associated keratins K15 and K19 in organ‐cultured HFs and/or isolated HF keratinocytes. PRL also up‐regulated K15 promoter activity and K15 protein expression in situ, whereas it inhibited K6 and K31 expression. These regulatory effects were reversed by a pure competitive PRL receptor antagonist. Antagonist alone also modulated keratin expression, suggesting that “tonic stimulation” by endogenous PRL is required for normal expression levels of selected keratins. Therefore, our study identifies PRL as a major, clinically relevant, novel neuroendocrine regulator of both human keratin expression and human epithelial stem cell biology in situ. —Ramot, Y., Bíro´, T., Tiede, S. To´th, B. I., Langan, E. A., Sugawara, K., Foitzik, K., Ingber, A., Goffin, V., Langbein, L., Paus, R. Prolactin—a novel neuroendocrine regulator of human keratin expression in situ. FASEB J. 24, 1768–1779 (2010). www.fasebj.org
FEBS Letters | 2009
Balázs István Tóth; Szilvia Benkő; Attila Gábor Szöllősi; László Kovács; Éva Rajnavölgyi; Tamás Bíró
The goal of the current study was to investigate the expression of transient receptor potential vanilloid‐1 (TRPV1) on human in vitro differentiated monocyte‐derived dendritic cells (DCs) and to dissect the corresponding role of TRPV1‐signaling in DC‐specific functions. TRPV1 expression was identified both at the protein and gene levels in human DCs. Moreover, the prototypic TRPV1 agonist capsaicin specifically (i.e. via TRPV1) and dose‐dependently inhibited cytokine‐induced DC differentiation, phagocytosis of bacteria, activation of DCs, and pro‐inflammatory cytokine secretion. These data introduce TRPV1‐coupled signaling as a novel player in human monocyte‐derived DC biology with anti‐inflammatory actions.